Navigation Links
Nile Therapeutics Reports 2009 First Quarter Financial Results
Date:5/14/2009

$0.13 per share, during the first quarter of 2008. Weighted-average shares outstanding for the quarter were 24.1 million.

Net cash used in operating activities in the first quarter of 2009 was $1.9 million. As of March 31, 2009, Nile had cash and cash equivalents of approximately $3.6 million compared to approximately $5.5 million as of December 31, 2008.

About Nile Therapeutics

Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the treatment of cardiovascular disease and other areas of unmet medical needs. Nile is initially focusing its efforts on developing its lead compound, CD-NP, a novel rationally designed chimeric peptide in clinical studies for the treatment of heart failure, and CU-NP, a novel rationally designed natriuretic peptide. A key component of the company's strategy is to acquire the global rights to additional compounds to expand its portfolio. More information on Nile can be found at http://www.nilethera.com.

Safe Harbor Paragraph for Forward-Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding the timing, progress and anticipated results of the clinical development, regulatory processes, clinical trial timelines, anticipated benefits of CD-NP, Nile's strategy, future operations, outlook, milestones, the timing and success of Nile's product development, future financial position, future financial results, plans and objectives of management are forward-looking statements. Nile may not actually achieve these plans, intentions or expectations and Nile cautions investors not to place
'/>"/>

SOURCE Nile Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Oxygen Biotherapeutics, Inc. Signs Cooperative Research and Development Agreement With Naval Medical Research Center and Walter Reed Army Institute of Research
2. Transition Therapeutics Announces Third Quarter Fiscal 2009 Financial Results
3. Medivation to Present at the Leerink Swann Novel Cancer Therapeutics Roundtable Conference
4. Nektar Therapeutics to Present at the Deutsche Bank 34th Annual Health Care Conference in Boston
5. Transition Therapeutics to Hold Conference Call on Third Quarter Fiscal 2009 Financial Results on Wednesday, May 13th, at 4:30 P.M. EST
6. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $20 Million of Common Stock and Warrants
7. Cell Therapeutics, Inc. Intends to Offer to Exchange up to $89.2 Million of its Outstanding Convertible Notes in a Modified Dutch Auction Tender Offer
8. Cornerstone Therapeutics Reports First Quarter 2009 Financial Results
9. Cornerstone Therapeutics Announces $70 Million Strategic Transaction With Chiesi Farmaceutici SpA
10. Cell Therapeutics Reports 76% Decrease in First Quarter 2009 Net Loss Attributable to Common Shareholders; Completion of Pixantrone NDA Submission on Track for Second Quarter 2009
11. Oxygen Biotherapeutics, Inc. Files Cosmetic Product Ingredient Statement for new Oxycyte-based Cosmetic Gel
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... CCL, a top-ranked, global provider of ... to other leadership development consultancies. “The CCL Partner ... successful practitioners, expanding our capacity to drive results for ... R. Ryan, CCL President and CEO. , As soon ... Network , it will schedule a one-on-one conference with ...
(Date:5/4/2015)... Diego, CA (PRWEB) May 04, 2015 ... a ribbon cutting ceremony at their brand new, 13,700 ... this year. The new building will not only provide ... population, but will also offer community and educational events ... The new facility is located next door to their ...
(Date:5/4/2015)... (PRWEB) May 04, 2015 Dr. Benjamin ... Georgia proudly offers the latest non-surgical double-chin eliminator. ... facial plastic surgeon in Atlanta to offer Kybella ... to be injected specifically under the chin, promising to ... , Before Kybella, patients who sought immediate solutions for ...
(Date:5/4/2015)... Unlike some camps, the Nike Middle School Running Camps are focused ... educate first and train second, with a significant amount of time ... are building the knowledge base needed to have a long and ... Effort Based Training, Running Heroes, Running Vocabulary, and Why am I ... not a camp where kids come to run and train hard ...
(Date:5/4/2015)... Dr. Richard Champagne, DMD, MAGD is pleased ... the America’s Best Dentist Award, given by the National ... top dentist is a reflection of his vast experience ... compassion for his patients. , Each year, the National ... their field. These nominees are dentists who have exceptionally ...
Breaking Medicine News(10 mins):Health News:The Center for Creative Leadership Is Partnering with Lead Star to Create the CCL Partner Network 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 2Health News:San Diego Fertility Center Hosted a Ribbon Cutting Ceremony at Its New, Expanded Facility 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2Health News:US Sports Camps and Select Nike Running Camps Offer Programs for Middle School Runners 2Health News:New Jersey Dentist Dr. Richard Champagne Nominated for America’s Best Dentist Award 2
... a daily basis has been stepped up in China, the ... out breaks of the much dreaded Avian influenza or “bird ... north-west regions two weeks ago. China has accelerated efforts to ... monitoring stations. The public at large and officials have been ...
... with a family history of lung cancer may be at ... new study. // ,Jun-Ichi Nitadori and colleagues at ... they looked into the health of more than 102,000 Japanese ... study, reported the online edition of health magazine WebMD. ...
... Injecting gold into knees affected by osteoarthritis may ease pain and ... it does not help everyone with rheumatoid arthritis. ,Arthritis ... the joints of the body. It is the leading cause of ... arthritis, each of which has a different cause. ,Researchers ...
... to shift gears and use decaffeinated coffee to avoid caffeine ... recent research and data compiled by the University of Florida ... caffeine. ,This month's Journal of Analytical Toxicology. has ... ,coffee which is one of the most prominent sources of ...
... all Public Offices across Bangkok the capital city of ... a senior official from the Bangkok Metropolitan Administration. ... Thai News Agency that the initial reforms have been ... BMA’s headquarters where smoking has already been prohibited in ...
... new survey showed that the total spending on Medicaid has ... was a reflection of a better economy// that has held ... federal Medicare drug benefit, according to a new survey. ,Medicaid ... has shown a growth of 2.8 percent in fiscal 2006, ...
Cached Medicine News:Health News:Decaffeinated Coffee... Not Really! 2Health News:Lowest Spending growth in US Medicaid 2
(Date:5/4/2015)... 4, 2015 EspeRare today announced ... Orphan Drug Designation (ODD) for rimeporide, its lead compound ... is a rare, life-threatening disease affecting boys early in ... is the most common and serious form of paediatric ... exchanger type-1 inhibitor, originally developed by Merck Serono in ...
(Date:5/1/2015)... The breakthrough hepatitis C treatment, Sovaldi faced ... Gilead Sciences overcame initial market resistance through its patient ... campaigns. Sovaldi,s high cure rate, short dosing ... the drug to $2.3 billion in sales during the ... the market. But Sovaldi,s price tag of $84,000 was ...
(Date:5/1/2015)... 1, 2015 Hitachi Chemical Diagnostics, Inc. is ... launch of the ExoComplete™ 96-Well Plate Kit and ... for exosome collection to mRNA purification.  The products were ... Annual Meeting, April 23 – 26, 2015, in ... for research use only of molecular biology applications and ...
Breaking Medicine Technology:EspeRare's Investigational Compound Rimeporide Receives European Orphan Drug Designation in Duchenne Muscular Dystrophy 2New Study Examines Success Lessons of Sovaldi's and Harvoni's Blockbuster Launches 2New Products for Exosome Isolation to mRNA Purification 2
... N.J., Oct. 19, 2011 Pacira Pharmaceuticals, Inc. ... data demonstrating a reduction in opioid burdens with EXPAREL™ ... and including 300 mg compared to bupivacaine HCl in ... the American College of Clinical Pharmacy (ACCP) in Pittsburgh. ...
... York eHealth Collaborative (NYeC) today announced the winners of its ... to the world of health information technology and healthcare. The ... NYeC Digital Health Conference 2011 on Thursday, Dec. 1. ... leading the advancement of health IT in New York State," ...
Cached Medicine Technology:Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 2Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 3Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 4Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 5Pacira Pharmaceuticals, Inc. Announces New Data Demonstrating Longer Time to First Opioid Use and Reduction in Opioid-Related Adverse Events With EXPAREL™ Compared to Bupivacaine HCl 6New York eHealth Collaborative Announces Winners for its Digital Health Conference Gala Awards 2
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Smooth pointed tips open to 3.0 mm. 45 degree cross action angled shafts. Tip to Angle Length: 12.0 mm. Round handle....
Flat handle 9 mm wide, angulated 45....
Straight shafts with pointed tips and 6 mm tying platform. Smooth handle with dull finish. Fine pointed tips....
Medicine Products: